M
Mark R. Brann
Researcher at ACADIA Pharmaceuticals Inc.
Publications - 77
Citations - 5729
Mark R. Brann is an academic researcher from ACADIA Pharmaceuticals Inc.. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 35, co-authored 77 publications receiving 5579 citations. Previous affiliations of Mark R. Brann include University of California, San Diego & Laboratory of Molecular Biology.
Papers
More filters
Journal Article
Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells.
TL;DR: The diverse binding profiles of individual cloned receptors and the widespread distribution of m1-m4 mRNAs indicate that radioligand binding studies performed on primary tissues may actually be assessing the composite properties of a heterogeneous mixture of muscarinic receptor subtypes.
Journal Article
Antagonist binding profiles of five cloned human muscarinic receptor subtypes.
TL;DR: The affinity profiles of several of these antagonists at five cloned human muscarinic receptors stably expressed in Chinese hamster ovary cells are determined.
Journal ArticleDOI
Human dopamine D1 receptor encoded by an intronless gene on chromosome 5.
Roger K. Sunahara,Hyman B. Niznik,David M. Weiner,Tom M. Stormann,Mark R. Brann,James L. Kennedy,Joel Gelernter,Richard Rozmahel,Yili Yang,Yedy Israel,Philip Seeman,Brian F. O'Dowd +11 more
TL;DR: The cloning of the D1 receptor gene is reported, which resides on an intronless region on the long arm of chromosome 5, near two other members of the G-linked receptor family, and binds drugs with affinities identical to the native human D1 receptors.
Journal ArticleDOI
Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia.
TL;DR: Detailed anatomical evidence is provided for the identity of the receptor subtypes which mediate the diverse effects of muscarinic and dopaminergic drugs on basal ganglia function.
Journal ArticleDOI
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.
D. M. Weiner,Herbert Y. Meltzer,Isaac Veinbergs,E. M. Donohue,Tracy A. Spalding,T. T. Smith,Nina Mohell,Scott C. Harvey,Jelveh Lameh,Norman Nash,Kimberly E. Vanover,Roger Olsson,Karuna Jayathilake,Myung A. Lee,Allan I. Levey,Uli Hacksell,Ethan S. Burstein,Robert E. Davis,Mark R. Brann +18 more
TL;DR: The muscarinic receptor agonist activities of NDMC are unique among antipsychotics, and provide a possible molecular basis for the superior clinical effects of clozapine pharmacotherapy.